Patients with stage IV ovarian cancer can derive long-term benefits from neoadjuvant pembrolizumab and chemotherapy if they achieve a major pathologic response, according to research published in ...

Clinical findings show association between nadunolimab and lower incidence and later onset of CIPNPreclinical data show prevention of ...

Clinical findings show association between nadunolimab and lower incidence and later onset of CIPN Preclinical data show ...